1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial

BACKGROUND: Oritavancin (ORI) is a lipoglycopeptide antibiotic approved in adults as a single 1,200 mg intravenous (IV) dose for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms, including methicillin-resistant Staphylococcus aureus. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, John, Arrieta, Antonio, Bokesch, Paula, Fusaro, Karen, Griffith, David C, Loutit, Jeffrey S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252426/
http://dx.doi.org/10.1093/ofid/ofy209.125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252426/
http://dx.doi.org/10.1093/ofid/ofy209.125

Ejemplares similares